Advanced search
Publication Cover
Journal of Medical Economics Volume 16, 2013 - Issue 3
Submit an article Journal homepage
1,061
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing–remitting multiple sclerosis in Sweden

Niklas BergvallNovartis Pharma AG BaselSwitzerlandCorrespondence[email protected]
,
Magnus TambourNovartis Sweden AB, Stockholm, Sweden
,
Freddie HenrikssonNovartis Sweden AB, Stockholm, Sweden
&
Sten FredriksonDepartment of Clinical Neuroscience, Karolinska Institute StockholmSweden
Pages 349-357 | Accepted 29 Nov 2012, Published online: 18 Dec 2012

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Olivier Outteryck. (2016) Natalizumab in relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics 16:5, pages 471-481.
Read now
Ken O’Day, Kellie Meyer, Dana Stafkey-Mailey & Crystal Watson. (2015) Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. Journal of Medical Economics 18:4, pages 295-302.
Read now
Niklas Bergvall, Raquel Lahoz, Tracy Reynolds & Jonathan R. Korn. (2014) Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Current Medical Research and Opinion 30:8, pages 1461-1471.
Read now
Radu Tanasescu & Cris S Constantinescu. (2014) Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism & Toxicology 10:4, pages 621-630.
Read now

Articles from other publishers (4)

Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Richard White. (2017) Building trust in real-world evidence and comparative effectiveness research: the need for transparency. Journal of Comparative Effectiveness Research 6:1, pages 5-7.
Crossref
Matteo Ruggeri, Andrea Aiello, Anna D'Ausilio, Eugenio Di Brino, Salvatore Cottone, Angelo Ghezzi, Lorella Lombardozzi, Alessandra Mecozzi, Dario Sacchini, Alessandro Roccia, Monica Mangone & Mondher Toumi. (2016) Evolution of the Healthcare Expenditure in Italy and Effects of Fingolimod Increased Prescribing in Second Line Treatment of Relapsing-Remitting Multiple Sclerosis. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 3:3, pages GRHTA.5000232.
Crossref
Mark Sanford. (2014) Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis. Drugs 74:12, pages 1411-1433.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.